| Literature DB >> 20429897 |
Krisztina Madách1, István Aladzsity, Agnes Szilágyi, George Fust, János Gál, István Pénzes, Zoltán Prohászka.
Abstract
INTRODUCTION: Activation of inflammation and coagulation are closely related and mutually interdependent in sepsis. The acute-phase protein, plasminogen activator inhibitor-1 (PAI-1) is a key element in the inhibition of fibrinolysis. Elevated levels of PAI-1 have been related to worse outcome in pneumonia. We aimed to evaluate the effect of functionally relevant 4G/5G polymorphism of PAI-1 gene in pneumonia induced sepsis.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20429897 PMCID: PMC2887202 DOI: 10.1186/cc8992
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Summary of patient characteristics stratified by multiple organ dysfunction, sepsis severity and mortality
| Multiple organ dysfunction | Sepsis severity | ICU mortality | ||||
|---|---|---|---|---|---|---|
| Patient characteristics | Non-MODS | MODS | Severe sepsis | Septic shock | Survivors | Non-survivors |
| Age (years) | 58.5 (48-68)* | 70 (59-77)* | 61 (51-71)* | 72 (59-77)* | 61 (50-70)* | 72.5(61-79)* |
| Male sex, % | 45.3 | 53.7 | 46.6 | 55.1 | 45.0 | 59.0 |
| Days of complaint before admission, (days) | 4 (2-7) | 4 (1-10) | 4 (2-8) | 4 (1-9) | 4 (1-7.5) | 4 (2-10) |
| Pulmonary hospitalisation in the past two years, % | 27.9 | 24.8 | 31.4* | 19.1* | 27.9 | 23.1 |
| Cachexia, % | 12.8 | 17.4 | 12.7 | 19.1 | 14.0 | 17.9 |
| Nosocomial pneumonia, % | 25.6* | 44.6* | 30.5* | 44.9* | 32.6 | 43.6 |
| Ischemic heart disease, % | 33.7 | 43.8 | 37.3 | 42.7 | 36.4 | 44.9 |
| COPD, % | 43.0 | 33.1 | 42.4 | 30.3 | 39.5 | 33.3 |
| Hypertension, % | 55.8 | 62.8 | 59.3 | 60.7 | 58.1 | 62.8 |
| Diabetes mellitus, % | 24.4 | 27.3 | 26.3 | 25.8 | 24.0 | 29.5 |
| Active and ever (>15 years) smoking, % | 46.5 | 42.1 | 46.6 | 40.4 | 46.5 | 39.7 |
| Alcohol consumption >1 glass/day, % | 9.3 | 13.2 | 9.3 | 14.6 | 10.9 | 12.8 |
| 28 days mortality, % | 0.0* | 62.8* | 9.3* | 73.0* | 0.0* | 97.4* |
| ICU mortality, % | 0.0* | 64.5* | 9.3* | 75.3* | - | - |
| APACHE II score at admission | 18 (14-22)* | 24 (18.5-30.5)* | 19 (15-23)* | 25 (20-31)* | 19 (15-23)* | 25 (22-31)* |
| DIC score at admission | 0 (0-2)* | 3 (0-4)* | 0 (0-2)* | 3 (2-5)* | 0 (0-2)* | 3 (2-4)* |
| ICU length of stay, (days) | 8 (5-12) | 8 (5-16.5) | 8 (5-12) | 8 (4.5-16.5) | 9 (5-15) | 8 (4-12) |
| Horowitz quotient of invasively ventilated patients, (PaO2/FiO2) | 269.0 (161.3-342.3)* | 179.6 (126.2-232.4)* | 222.0 (149.9-335.4)* | 175.2 (119.7-229.7)* | 197.5 (139.1-305.5) | 188.3 (124.2-241.6) |
| ARDS, % | 7.0* | 24.0* | 8.5* | 28.1* | 11.6* | 25.6* |
| Invasive ventilation, % | 52.3* | 97.5* | 62.7* | 100.0* | 65.9* | 100.0* |
| Length of invasive ventilation, (days) | 5 (3.5-7.5)* | 8 (4-13.3)* | 5.5 (4-10.3) | 7 (4-14) | 6 (4-13) | 7 (4-12) |
| Tracheotomy, % | 5.8* | 14.9* | 10.2 | 12.4 | 10.9 | 11.5 |
| Hemodialysis, % | 7.0* | 17.4* | 9.3 | 18.0 | 9.3* | 19.2* |
| Unconfirmed, | 55.8* | 31.4* | 49.2* | 31.5* | 45.0 | 35.9 |
| Confirmed, | ||||||
| Gram positive | 10.5 | 19.3 | 11.7 | 21.3 | 15.5 | 18.0 |
| Gram negative | 52.6 | 57.8 | 60.0 | 52.5 | 52.1 | 62.0 |
| Atypical pneumonia (Chlamydia, Mycoplasma, Legionella) | 23.7 | 14.5 | 18.3 | 16.4 | 21.1 | 12.0 |
| Mixed | 13.2 | 8.4 | 10.0 | 9.8 | 11.3 | 8.0 |
*Statistical significance (P < 0.05) of comparing the groups of non-MODS vs. MODS, severe sepsis vs. septic shock and survivors vs. non-survivors by Mann-Whitney or Pearson Chi-square tests
APACHE II, acute physiology and chronic health evaluation II; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; DIC, disseminated intravascular coagulation; FiO2, fraction of inspired oxygen; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of arterial oxygen.
The incidence of MODS, septic shock and non-survival in carriers of the different PAI-1 4G/5G genotypes
| Genotype | n | MODS (%) | Septic shock (%) | Non-survivors (%) |
|---|---|---|---|---|
| 4G/4G | 63 | 39 (61.9%) | 32 (50.8%) | 27 (42.9%) |
| 4G/5G | 105 | 67 (63.8%) | 47 (44.8%) | 41 (39.0%) |
| 5G/5G | 39 | 15 (38.5%) | 10 (25.6%) | 10 (25.6%) |
MODS, multiple organ dysfunction syndrome; PAI-1, plasminogen activator inhibitor 1.
Distribution of PAI-1 4G/5G genotypes and alleles as stratified according to multiple organ dysfunction, sepsis severity and mortality
| Multiple organ dysfunction | Sepsis severity | ICU mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-MODS (n = 86) | MODS | Severe sepsis | Septic shock | Survivors | Non-survivors (n = 78) | ||||
| 4G/4G and 4G/5G | 62 (72.1%) | 106 (87.6%) | 89 (75.4%) | 79 (88.8%) | 100 (77.5%) | 68 (87.2%) | |||
| 5G/5G | 24 (27.9%) | 15 (12.4%) | 0.005 | 29 (24.6%) | 10 (11.2%) | 0.015 | 29 (22.5%) | 10 (12.8%) | 0.085 |
| 4G | 86 (50.0%) | 145 (59.9%) | 120 (50.8%) | 111 (62.4%) | 136 (52.7%) | 95 (60.9%) | |||
| 5G | 86 (50.0%) | 97 (40.1%) | 0.045 | 116 (49.2%) | 67 (37.6%) | 0.019 | 122 (47.3%) | 61 (39.1%) | 0.104 |
*Pearson Chi-square tests
MODS, multiple organ dysfunction syndrome; PAI-1, plasminogen activator inhibitor 1.
Multivariate logistic regression analysis of MODS, septic shock and ICU mortality
| MODS | Septic shock | ICU mortality | ||||
|---|---|---|---|---|---|---|
| Odds ratio | Odds ratio | Odds ratio | ||||
| Age, years | 1.048 (1.027-1.069) | <0.001 | 1.032 (1.013-1.052) | 0.001 | - | - |
| Nosocomial infection | 3.029 (1.503-6.102) | 0.002 | 2.047 (1.104-3.797) | 0.023 | - | - |
| Positive microbiological culture | 3.642 (1.876-7.069) | <0.001 | 2.365 (1.275-4.386) | 0.006 | - | - |
| APACHE II | - | - | - | - | 1.158 (1.101-1.217) | <0.001 |
| 5G/5G | reference group | reference group | reference group | |||
| 4G/5G and 4G/4G | 2.957 (1.306-6.698) | 0.009 | 2.603 (1.137-5.959) | 0.024 | 1.998 (0.879-4.540) | 0.098 |
APACHE II, acute physiology and chronic health evaluation II; MODS, multiple organ dysfunction syndrome.